This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

L-Arginine, Vascular Response and Mechanisms

This study has been completed.
Information provided by (Responsible Party):
Naomi DL Fisher, MD, Brigham and Women's Hospital Identifier:
First received: November 28, 2011
Last updated: July 27, 2016
Last verified: July 2016
The purpose of the study is to employ the supplement L-arginine to test the hypothesis that activation of blood flow to the brain during cognitive tasks is regulated by nitric oxide in older subjects with diabetes mellitus and/or hypertension (high blood pressure).

Condition Intervention Phase
Hypertension Diabetes Dietary Supplement: L-Arginine Dietary Supplement: Placebo Supplement Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: L-Arginine, Vascular Response and Mechanisms

Resource links provided by NLM:

Further study details as provided by Naomi DL Fisher, MD, Brigham and Women's Hospital:

Primary Outcome Measures:
  • Functional transcranial doppler measures [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • Flow Mediated Dilation (FMD) [ Time Frame: 6 weeks ]
  • Finger Blood Flow - Plethysmography (PAT) [ Time Frame: 6 weeks ]

Enrollment: 25
Study Start Date: April 2012
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: L-arginine Dietary Supplement: L-Arginine
Dietary Supplement
Placebo Comparator: Placebo Supplement Dietary Supplement: Placebo Supplement
Dietary Supplement


Ages Eligible for Study:   70 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diabetes and/or hypertension

Exclusion Criteria:

  • alzheimers disease, dementia, stroke, active herpes, recent angina or heart attack
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01482247

United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Principal Investigator: Naomi Fisher, MD Brigham and Women's Hospital
  More Information

Responsible Party: Naomi DL Fisher, MD, Principal Investigator, Brigham and Women's Hospital Identifier: NCT01482247     History of Changes
Other Study ID Numbers: 2008A052379
Study First Received: November 28, 2011
Last Updated: July 27, 2016 processed this record on September 19, 2017